Patents by Inventor Christina A. Scherer
Christina A. Scherer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120258908Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: ApplicationFiled: February 1, 2012Publication date: October 11, 2012Applicant: KINETA TWO, LLCInventors: SHAWN P. IADONATO, CHARLES L. MAGNESS, MARK BRANUM, MARALEE MCVEAN, CHRISTINA SCHERER
-
Publication number: 20120253027Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.Type: ApplicationFiled: November 22, 2011Publication date: October 4, 2012Applicant: KINETA TWO, LLPInventors: Shawn P. Iadonato, CHARLES L. MAGNESS, GARY ROSENBERG, CHRISTINA A. SCHERER, THIERRY GUILLAUDEUX
-
Patent number: 8192973Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.Type: GrantFiled: November 2, 2006Date of Patent: June 5, 2012Assignee: Kineta Two, LLCInventors: Shawn P Iadonato, Charles L Magness, Gary Rosenberg, Christina A Scherer, Thierry Guillaudeux
-
Publication number: 20120070424Abstract: Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided.Type: ApplicationFiled: July 11, 2011Publication date: March 22, 2012Inventors: Shawn P. Iadonato, Charles L. Magness, P. Campion Fellin, Christina A. Scherer, Tory Hagen, Amy Olson
-
Patent number: 8133710Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: GrantFiled: March 30, 2010Date of Patent: March 13, 2012Assignee: Kineta Two, LLCInventors: Shawn P Iadonato, Charles L Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Patent number: 8088907Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.Type: GrantFiled: April 2, 2008Date of Patent: January 3, 2012Assignee: Kineta Two, LLCInventors: Shawn P. Iadonato, Charles L. Magness, Gary Rosenberg, Christina A. Scherer, Thierry Guillaudeux
-
Patent number: 8030046Abstract: Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided.Type: GrantFiled: October 9, 2008Date of Patent: October 4, 2011Assignee: Kineta Two, LLCInventors: Shawn P. Iadonato, Charles L. Magness, P. Campion Fellin, Christina A. Scherer, Tory Hagen, Amy Olson
-
Publication number: 20110237501Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.Type: ApplicationFiled: April 7, 2011Publication date: September 29, 2011Inventors: Shawn P. Iadonato, Charles L. Magness, Gary Rosenberg, Christina A. Scherer, Thierry Guillaudeux
-
Publication number: 20110071073Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.Type: ApplicationFiled: November 2, 2006Publication date: March 24, 2011Applicant: Illumigen Biosciences, Inc.Inventors: Shawn P. Iadonato, Charles L. Magness, Gary Rosenberg, Christina A. Scherer
-
Publication number: 20100256348Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: ApplicationFiled: March 30, 2010Publication date: October 7, 2010Applicant: ILLUMIGEN BIOSCIENCES, INC.Inventors: Shawn P. Iadonato, Charles L. Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Patent number: 7732177Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: GrantFiled: November 17, 2006Date of Patent: June 8, 2010Assignee: Illumigen Biosciences, Inc.Inventors: Shawn P. Iadonato, Charles L. Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Publication number: 20090291074Abstract: Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided.Type: ApplicationFiled: October 9, 2008Publication date: November 26, 2009Applicant: Illumigen Biosciences Inc.Inventors: Shawn P. IADONATO, Charles L. Magness, P. Campion Fellin, Christina A. Scherer, Tory Hagen, Amy Olson
-
Publication number: 20090186028Abstract: A method for detecting a mutation related to the gene encoding LDLR. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the wild-type and mutated genes, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human LDLR, including antisense oligonucleotides, methods, and compositions specific for human LDLR, are also provided.Type: ApplicationFiled: June 27, 2005Publication date: July 23, 2009Applicant: Illumigen Biosciences, Inc.Inventors: Shawn P. Iadonato, Charles L. Magness, Christina A. Scherer
-
Publication number: 20090155234Abstract: A method for detecting a mutation related to the gene encoding MxA. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the wild-type and mutated genes, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human MxA, including antisense oligonucleotides, methods, and compositions specific for human MxA, are also provided.Type: ApplicationFiled: August 25, 2006Publication date: June 18, 2009Applicant: Cubist Pharmaceuticals, Inc.Inventors: Charles L. Magness, Shawn P. Iadonato, Christina A. Scherer, Phillip Campion Fellin, Kathryn V. Steiger
-
Publication number: 20090123472Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.Type: ApplicationFiled: April 2, 2008Publication date: May 14, 2009Applicant: Illumigen Biosciences, Inc.Inventors: Shawn P. Iadonato, Charles L. Magness, Gary Rosenberg, Christina A. Scherer
-
Publication number: 20080124311Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: ApplicationFiled: November 17, 2006Publication date: May 29, 2008Applicant: Illumigen Biosciences, Inc.Inventors: Shawn P. Iadonato, Charles L. Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Publication number: 20070154467Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.Type: ApplicationFiled: November 2, 2006Publication date: July 5, 2007Applicant: Illumigen Biosciences, Inc.Inventors: Shawn Iadonato, Charles Magness, Gary Rosenberg, Christina Scherer, Thierry Guillaudeux
-
Publication number: 20070111231Abstract: Compositions and methods are provided for detecting a mutation in a human oligoadenylate synthetase gene, particularly OAS2 or OAS3, wherein the mutation confers resistance to flavivirus infection, including infection by hepatitis C virus, and the mutation relates to other disease states including prostate cancer and diabetes, and uses of the encoded proteins and antibodies thereto.Type: ApplicationFiled: August 23, 2006Publication date: May 17, 2007Applicant: Illumigen Biosciences, Inc.Inventors: Charles Magness, Shawn Iadonato, Christina Scherer, Phillip Fellin, Kathryn Steiger
-
Publication number: 20060275802Abstract: Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided.Type: ApplicationFiled: May 3, 2006Publication date: December 7, 2006Inventors: Shawn Iadonato, Charles Magness, P. Fellin, Christina Scherer, Tory Hagen, Amy Olson
-
Publication number: 20050191649Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.Type: ApplicationFiled: October 22, 2004Publication date: September 1, 2005Applicant: Illumigen Biosciences, Inc.Inventors: Shawn Iadonato, Charles Magness, Gary Rosenberg, Christina Scherer